[go: up one dir, main page]

WO2019004776A3 - Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same - Google Patents

Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same Download PDF

Info

Publication number
WO2019004776A3
WO2019004776A3 PCT/KR2018/007402 KR2018007402W WO2019004776A3 WO 2019004776 A3 WO2019004776 A3 WO 2019004776A3 KR 2018007402 W KR2018007402 W KR 2018007402W WO 2019004776 A3 WO2019004776 A3 WO 2019004776A3
Authority
WO
WIPO (PCT)
Prior art keywords
montelukast
improved stability
preparing
chewable tablet
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/007402
Other languages
French (fr)
Other versions
WO2019004776A2 (en
Inventor
Taek Kwan Kwon
Kwang Young Lee
Ho Taek IM
Youg Il KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180047553A external-priority patent/KR102110304B1/en
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of WO2019004776A2 publication Critical patent/WO2019004776A2/en
Publication of WO2019004776A3 publication Critical patent/WO2019004776A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un comprimé à mâcher composite comprenant de la lévocétirizine et du montélukast, qui présente une stabilité et une observance médicamenteuse améliorées par masquage d'un goût amer, et son procédé de préparation.The invention relates to a composite chewable tablet comprising levocetirizine and montelukast, which has improved stability and drug compliance by masking a bitter taste, and a process for its preparation.

PCT/KR2018/007402 2017-06-30 2018-06-29 Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same Ceased WO2019004776A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0083824 2017-06-30
KR20170083824 2017-06-30
KR10-2018-0047553 2018-04-24
KR1020180047553A KR102110304B1 (en) 2017-06-30 2018-04-24 Composite chewable tablet comprising levocetirizine and montelukast with improved stability and adaptability of taking medicine and a process for the preparation thereof

Publications (2)

Publication Number Publication Date
WO2019004776A2 WO2019004776A2 (en) 2019-01-03
WO2019004776A3 true WO2019004776A3 (en) 2019-04-11

Family

ID=64742475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/007402 Ceased WO2019004776A2 (en) 2017-06-30 2018-06-29 Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same

Country Status (1)

Country Link
WO (1) WO2019004776A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112674300B (en) * 2020-12-15 2023-06-09 四川安岳中柠柠檬产业技术研究有限公司 Lemon chewable tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
US20130085124A1 (en) * 2010-06-16 2013-04-04 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US20160367551A1 (en) * 2013-06-28 2016-12-22 Hanmi Pharm. Co., Ltd Complex granule formulation having improved stability comprising levocetirizine and montelukast

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
WO2011110939A2 (en) * 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
US20130085124A1 (en) * 2010-06-16 2013-04-04 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US20160367551A1 (en) * 2013-06-28 2016-12-22 Hanmi Pharm. Co., Ltd Complex granule formulation having improved stability comprising levocetirizine and montelukast

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ASHRAFA, SYED ET AL.: "Formulation and in-vitro evaluation of Levocetirizine dihydrochloride and Montelukast sodium bilayered tablet for bi-modal drug release", INDIAN JOURNAL OF RESEARCH IN PHARMACY AND BIOTECHNOLOGY, vol. 2, no. 6, 2014, pages 1460 - 1464, XP055590094 *

Also Published As

Publication number Publication date
WO2019004776A2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
EP3750887A4 (en) BIARYLE DERIVATIVE, ITS PREPARATION PROCESS, AND ITS PHARMACEUTICAL APPLICATION
IL286471A (en) The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient
EA201691448A1 (en) HYBRIDOSOMES CONTAINING THEIR COMPOSITIONS, METHODS OF THEIR PRODUCTION AND THEIR APPLICATION
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
CA2977150A1 (en) Antiviral compounds
EP3398939A4 (en) ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL APPLICATIONS THEREOF
EP3647310A4 (en) PROCESS FOR THE PREPARATION OF 2,5-FURANDIMETHYLCARBOXYLATE FROM HYDROXYMETHYLFURFURAL
PH12019501955A1 (en) Tri-cycle compound and applications thereof
HK1246780A1 (en) Aza-pyridone compounds and uses thereof
MY204563A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2017013498A3 (en) Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
SG11202104269PA (en) Anti-her2 antibody drug conjugate pharmaceutical preparation
WO2019194773A3 (en) The combination comprising linagliptin and metformin
WO2018193090A3 (en) Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2019004776A3 (en) Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same
WO2017068388A3 (en) Use of synthetic pntx-19 peptide for the treatment of pain
WO2019059868A3 (en) Pharmaceutical combinations comprising tenofovir, emtricitabine and efavirenz
WO2018094035A3 (en) Ligand ionophore conjugates
IL284132A (en) Pharmaceutical compound, the method of its making and use as medicinal agent
MX2016017315A (en) Pharmaceutical dosage forms.
EP3808728A4 (en) METHOD FOR THE PREPARATION OF 3(4),8(9)-BISFORMYLTRICYCLO[5.2.1.0²,6]DECANE
EA202090333A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING AN ANTIBODY TO BST1 AND ANALOGUE OF CYTIDINE
EA202000127A1 (en) DRUG FOR CELLIAKIA TREATMENT AND METHOD FOR ITS OBTAINING
MX2020001681A (en) Pharmaceutical composition for prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan, and rosuvastatin, and composite preparation including the same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18825266

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18825266

Country of ref document: EP

Kind code of ref document: A2